Material and Methods: We used a prospective, longitudinal design with random assignment to the control (CG) and intervention (IG) groups. We obtained informed consent from all participants and collected data at baseline (T0 – before BC surgery), 2 weeks (T1) and 3 months (T2 – after BC surgery). We measured shoulder ROM (flexion, abduction, external rotation) with a standard goniometer (degrees); deltoid and grip strengths with hand held dynamometers (meter-kgs); average pain (0 = no pain; 10 = severe). All received pre-operative usual care education and IG received additional 1:1 instruction on the use of MOVE-ABC materials and an intervention survey on content and timing of delivery. We calculated change scores (T0 – T1; T0 – T2) for ROM, strength and pain variables. We analyzed data for trends with medians (25th – 75th percentiles) for continuous data and frequencies for categorical data. Results: We recruited 56 female BC survivors (100 eligible) and retained 24 with complete data (n C = 9; n I = 15); 23 are white (median age 53 years); 44% of CG and 60% of IG had BCA on the dominant side. From T0 – T2, IG had slightly more flexion and abduction (median = +3 degrees over baseline) whereas CG had less (median = -10 and -5, respectively). IG returned to baseline for external rotation whereas CG had slight improvement (median = +4 degrees). Pain and strength (deltoid, grip) were similar across time for both groups. IG agreed (100%) that MOVE-ABC had acceptable and useful information for impairment management and that the best time to receive MOVE-ABC is before BC surgery. Conclusions: The IG had improved ROM with the added benefit that pre- surgical education about impairment management was useful and accept- able. These results must be interpreted cautiously but suggest that MOVE- ABC might hold potential to fill a gap in patient education for early identification and control of BC-related impairments. Our next step is to test MOVE-ABC in a large randomized and investigator-blinded trial to determine efficacy of the intervention. No conflict of interest 170 (PB-071) Poster Effectiveness of two compression methods in the treatment of breast cancer related upper limb lymphedema V. Pujol 1 , S. Salinas 2 , R. Belmonte 3 , T. Pascual 4 , M.L. Catasus 5 , A. Gomez-Garrido 6 , A. Lobato 3 . 1 Hospital Universitari Vall d’ Hebron, Physical Medicine and Rehabilitation Department, Barcelona, Spain; 2 Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain; 3 Hospital Mar-Esperança, Parc de Salut Mar, Barcelona, Spain; 4 Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 5 Hospitalet de Llobregat, Spain; 6 Barcelona, Spain Trial abbreviation: Effectiveness of Two Compression Methods in the Treatment of Upper Limb Lymphedema Trial registry number: ClinicalTrials.gov ID: NCT02369679 Trial status: completed Trial sponsor: Parc de Salut Mar Background: Treatment of lymphedema is based on complex deconges- tive therapy. Multilayer compression bandage (MCB) has proved to be the most effective of the components when analyzed separately. MCB requires careful application by expert professionals and needs several materials. The precast adjustable compression wrap (PACW) is proposed as an alternative system for the treatment of lymphedema through a Velcro® system that allows an easy use. The purpose of the present study was to compare the effectiveness of PACW vs. MCB in the decongestive treatment of breast cancer related upper limb lymphedema. Methods: Design: multicenter randomized single blind controlled trial Population: patients with upper limb lymphedema after axillary node dissection for breast cancer. Sample size was obtained considering the effectiveness of MCB of 37.2% (SD 17.9) of volume reduction. A total of 18 individuals were needed at each group to detect a difference equal o major of 15 units, with alfa = 0.05 and power of 80%. The total sample was increased in order to prevent a 30% loss in follow-up. Intervention: A physiotherapist applied a lymphatic drainage to the affected upper limb and then applied the MCB (active comparator) or the PACW (intervention) according to allocation. Patients would maintain compression until the next session of treatment. The first 10 sessions will be daily, and then on alternate days (3 per week) until the patient receive a tailored compression garment. Primary outcome was the percentage reduction of the excess of volume of the lymphedema at 10th session and 3 months. Secondary outcomes were the change in visual analogue scale values of pain, heaviness, tightness and hardness. Analyses were performed by an intention-to-treat approach. Baseline characteristics were compared between groups by analysis of variance Evolution for each dependent variable was analyzed using linear-mixed models for repeated measures. An interaction term (time by group) was added to check differences between groups in the evolution of dependent variables. Results: 42 patients were analyzed, 22 to PACW and 20 to MCB group. At 10th session the excess of volume decreased a mean of 15.8% in PACW group and. a mean of 27.6% in MCB group. At 3 months, the excess of volume respect baseline decreased 21.3% and 16.6% respectively on PACW and MCB groups. Both treatments achieved significant decrease in symptoms along time. There were no significant differences between PACW and MCB at 10th session and at 3 months of follow up. Conclusion: The PACW system was as useful as MCB, so PACW could be an alternative in the decongestive phase of treatment of upper limb lymphedema. No conflict of interest Wednesday, 21 March 2018 POSTER SESSION Risk Factors 171 (PB-072) Poster Higher risk of contralateral breast cancer in younger women with HER2/ neu-positive primary breast cancer T.I. Yoon 1 , O.V. Yi 1 , H.J. Kim 2 . 1 Division of Breast Surgery, Department of Surgery, Dongnam Institute of Radiological and Medical Science, Busan, Korea; 2 University of Ulsan College of Medicine, Asan Medical Center, Division of Breast Surgery, Department of Surgery, Seoul, Korea Background: Young age is an important risk factor for contralateral breast cancer (CBC). This study analyzed the relative risk factors and annual hazard risk for CBC according to age. Patients and methods: After correcting for tumor size, node metastasis, grade, and subtype, we created a matched cohort with 8716 patients diagnosed with invasive breast cancer for the first time from January 1989 to December 2008 to analyze the relative risk factors, survival, and annual risk of CBC according to age. Results: The median follow-up duration was 129 months. Of 652 patients under the age of 35 years, CBC occurred in 43 patients (6.6%), whereas CBCs occurred in 65 of 2608 patients (2.5%) over the age of 35. According to multivariate analysis, the relative risk of CBC in the younger group was 2.48 (95% confidence interval [CI] 1.13–3.01). In particular, the risk was significantly higher for younger patients with a HER2-overexpressing tumor (hazard ratio 4.98, 95% CI 2.19–11.33), family history (hazard ratio 7.79, 95% CI 2.44–24.85), and anti-hormone therapy (hazard ratio 3.46, 95% CI 1.88–6.35). Regarding the annual CBC risk pattern, the occurrence of CBC was high within 5 years after surgery in patients with HER2-positive cancer and more than 5 years after the surgery in the case of hormone receptor-positive cancer. In the case of tripe-negative disease, the occurrence steadily increased over time. Table 1 Relative Risks (RR) of Contralateral Breast Cancer associated with age <35 yr ≥35 yr Adjusted P value Total (N) CBC (N) Total (N) CBC (N) Hazard Ratio 95% CI Overall 652 43 2608 65 2.483 1.698 3.631 0.000 Subtype HR + Her2- 309 10 1236 20 2.474 1.136 5.389 0.023 HR + Her2+ 95 7 380 7 5.292 1.994 14.046 0.001 HR-Her2+ 79 5 316 4 4.948 1.161 21.095 0.031 HR-Her2- 169 21 676 34 2.001 1.204 3.327 0.007 Endocrine therapy Yes 381 18 1671 27 3.457 1.882 6.350 0.000 No 264 23 905 38 1.843 1.129 3.010 0.015 Chemotherapy Yes 554 41 1907 54 2.581 1.741 3.825 0.000 No 97 2 681 11 2.525 0.542 11.760 0.238 Family history No 593 34 2391 61 2.085 1.366 3.181 0.001 Yes 59 9 215 4 7.786 2.439 24.854 0.001 BMI group <18.5 76 7 80 1 5.083 0.612 42.180 0.132 18.5–24.9 477 32 1788 41 2.790 1.758 4.429 0.000 ≥25 96 4 729 23 1.261 0.422 3.769 0.678 European Journal of Cancer 92, Suppl. 3 (2018) S17–S160 S41 Abstracts, EBCC 11 Poster Session (Wednesday, 21 March 2018)